Why Cannabis Genetics Matter & How to Invest in Innovations
April 25th, 2019
App, Exclusive, News, Top News
Cannabis cultivators and budtenders love to talk about genetics. While everyone has an opinion on the effects of specific strains, recent research suggests that the effects of cannabis aren’t necessarily consistent with strains, and the generally accepted classifications of indiva, sativa and hybrid varieties may be flawed. Very few companies are investing in truly understanding cannabis genetics, creating new strains, and patenting them.
In this article, we will look at the importance of cannabis genetics and The Supreme Cannabis Company Inc.’s (TSX: FIRE) (OTCQB: SPRWF) (FRA: 53S1) recent move to focus on cannabis genetics as a key differentiator in the space.
Cannabis Genetics Decoded
The biggest problem with cannabis genetics is basic quality control. According to one study, 35 percent of more than 80 strains tested had genetics that didn’t match the strain that was being sold. Consumers were buying Sativa strains that were advertised as Indica and Indica strains being advertised as Sativa. Consumers have gravitated towards brands that they can trust to deliver a consistent experience by properly labeling strains.
In addition to accurate labeling, cannabis genetics is important for creating the desired effects in consumers and patients. Medical cannabis patients have very different requirements than recreational cannabis users, and understanding and fine-tuning the genetics can help cater products to both of these end markets. With more than 25,000 different genes in the cannabis plant, research in this area is only starting to scratch the surface of what’s possible.
Cannabis genetics are important for cultivators looking to create proprietary products. With a detailed understanding of the underlying genetics, cultivators can file for patents and license strains to other growers. These dynamics could pave the way for pharmaceutical-grade cannabis products, as well as innovative new licensing-based business models. Companies involved early on in these trends could benefit the most from the long-term potential.
Supreme Focuses on Genetics
There are several companies focused on understanding and leveraging cannabis genetics to their advantage, but few have the experience necessary to truly drive significant value. Supreme Cannabis is a Canadian licensed producer that recently formed a new wholly-owned subsidiary, Cambium Plant Sciences, to lead the agricultural revolution of cannabis genetics, redefine consumer experiences, and improve cultivation economics worldwide.
“Our proprietary genetics selection methodology and ability to cultivate high-end cannabis at scale at 7ACRES has created strong industry demand for our proprietary genetics and cultivation techniques,” said Supreme Cannabis CEO Navdeep Dhaliwal. “It was as a result of the demand that we saw a global opportunity to create a company whose sole focus is innovating plant genetics and cultivation IP for the global cannabis market. We believe genetics are the foundation of proprietary cannabis products in the long term.”
Cambium Plant Sciences will develop cultivars that benefit the company’s in-house brands, as well as their domestic and global cultivation and manufacturing partners. Using 7ACRES’ established genetics, existing infrastructure, and experienced team, the company will enjoy a significant advantage in scaling up its understanding of plant genetics and gain long-term access to the technologies needed to scale up production.
The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQB: SPRWF) (FRA: 53S1) will invest approximately $14 million in developing a leading research and innovation facility to house the new subsidiary. The facility will include proprietary grow rooms, breeding rooms, and supporting infrastructure in an existing 34,000 sq. ft. facility. Management has already commenced the licensing process and will begin retrofitting the facility early this summer.
Investors may want to take a closer look at the company given these efforts. In addition to supporting the improvement of its existing award-winning products, the move could pave the way toward lucrative new business models and licensing agreements.
For more information, visit the company’s website at www.supreme.ca.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.